Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q4 2019 · 10-K
Revenue$624.47M$624.47Mderived+1.2% vs Q4 2018 Net Income$553.50M$553.50MN/M vs Q4 2018 EPS Diluted$18.31$18.31N/M vs Q4 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
−0.7%
Operating Incomederived$59,205,000N/M Operating Cash Flowderived$159,802,000+52.2% Free Cash Flowderived$138,204,000+170.3% Margins · derivedGross margin52.9%−1.0 pt vs Q4 2018
Operating margin9.5%+46.3 pt vs Q4 2018
Net margin88.6%+223.0 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 2, 2020 · 62 d after period end